ACM
UTHR icon

ACT Capital Management’s United Therapeutics UTHR Stock Holding History

ACT Capital Management’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-13,500
Closed -$2.92M – 98
2021
Q4 		$2.92M Buy
13,500
+3,000
+29% +$589K 2.11% 10
2021
Q3 		$1.94M Hold
10,500
– – 1% 21
2021
Q2 		$1.88M Buy
+10,500
New +$2M 0.97% 26

Other funds holding UTHR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return

ACT Capital Management's UTHR Position: Q1 2022 in Review

ACT Capital Management sold out of United Therapeutics (UTHR) in Q1 2022, closing a stake of 13,500 shares — an estimated $2.92M sold.

ACT Capital Management first reported a position in UTHR in Q2 2021 and held it in 3 quarters. The position peaked at $2.92M in Q4 2021. 427 funds tracked by Wall St. Rank hold UTHR as of Q1 2022.

  • ACT Capital Management reported no remaining United Therapeutics position as of Q1 2022 after selling out during the quarter.
  • ACT Capital Management sold 13,500 United Therapeutics shares in Q1 2022, an estimated $2.92M.
  • ACT Capital Management first reported a position in United Therapeutics in Q2 2021 and held it in 3 quarters.
  • ACT Capital Management's United Therapeutics position peaked at $2.92M in Q4 2021.
  • 427 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2022.

Based on ACT Capital Management's 13F filing for Q1 2022, filed 11 May 2022.